PURPOSE

This study aimed to evaluate the effect of radiotherapy (RT) on symptomatic relief and tumor control in patients with breast cancer with skin involvement.

MATERIALS AND METHODS

This retrospective study included patients who received palliative RT of the breast or chest wall for breast cancer with skin involvement. Progression-free survival, freedom from local progression (FFLP), and symptomatic response were evaluated. The prescribed dose to tumor was calculated as the biologically effective dose (BED) using α/β of 4. Symptomatic responses were evaluated until 6 months after RT.

RESULTS

Of the 43 patients included in this study, 48 Gy in 15 fractions was the most common regimen, and the median BED was 86.4 Gy (range, 24.0 to 120.0). With a median follow-up of 15.1 months (range, 1.6 to 63.5), the median FFLP and progression-free survival were 8.4 and 3.6 months, respectively. The 1-year FFLP rates in patients who received BED >75 Gy and BED ≤75 Gy were 78.3% and 49.7%, respectively (p = 0.046). Within 6 months after RT, 75% of patients showed relief of discharge, 67% showed relief of bleeding, and 37% showed relief of pain. There was no grade 3 or higher skin toxicity or other adverse events.

CONCLUSION

Palliative RT is a safe and effective treatment option for patients with breast cancer with skin involvement, providing symptomatic relief. The administration of BED ≥75 Gy can offer a benefit in achieving durable local control.